Accéder au contenu
Merck
Toutes les photos(2)

Key Documents

C9756

Sigma-Aldrich

Cholécalciférol

≥98% (HPLC)

Synonyme(s) :

(+)-Vitamine D3, 7-Déhydrocholestérol activé, 7-déhydrocholestérol activé, Cholécalciférol

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C27H44O
Numéro CAS:
Poids moléculaire :
384.64
Numéro Beilstein :
2339331
Numéro CE :
Numéro MDL:
Code UNSPSC :
12352209
eCl@ss :
34058003
ID de substance PubChem :
Nomenclature NACRES :
NA.26

Source biologique

synthetic (organic)

Niveau de qualité

Pureté

≥98% (HPLC)

Forme

powder

Technique(s)

HPLC: suitable

Couleur

white to off-white

Pf

83-86 °C (lit.)

Température de stockage

2-8°C

Chaîne SMILES 

CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C

InChI

1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1

Clé InChI

QYSXJUFSXHHAJI-YRZJJWOYSA-N

Informations sur le gène

human ... VDR(7421)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Cholecalciferol acts as a hormone precursor since it requires two stages of metabolism: first to 25-hydroxycholecalciferol; then to 1α, 25-dihydroxycholecalciferol. One unit (U.S.P. or international) is defined as the activity of 0.025 μg of vitamin D3 contained in the USP vitamin D reference standard.
Cholecalciferol is sourced either through the diet or exposing skin to ultraviolet rays. Oral administration of vitamin D3 is readily absorbed and is stored in adipose tissue.

Application


  • Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation.: This study delves into the significant roles of cholecalciferol in modulating the renal-bone axis, inflammatory responses, and iron metabolism in elderly patients with renal impairment. Through vitamin D supplementation, researchers observed pivotal changes that could guide future therapeutic strategies (Christodoulou M et al., 2024).

  • Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study.: This clinical trial assesses the efficacy of cholecalciferol in improving the health outcomes of patients with multiple sclerosis. The use of cholecalciferol potentially enhances neurological function and reduces disease progression, illustrating its vital role in neurodegenerative disease management (Maghbooli Z et al., 2024).

  • Vitamin D regulates COVID-19 associated severity by suppressing the NLRP3 inflammasome pathway.: This pivotal research links cholecalciferol to the reduction of COVID-19 severity through its regulatory effects on the NLRP3 inflammasome pathway. The findings underscore the potential of vitamin D as a modulatory agent in the immune response against viral infections (Khalil B et al., 2024).

  • Effects of Vitamin D Supplementation on Central Hemodynamic Parameters and Autonomic Nervous System in Obese or Overweight Individuals.: This randomized controlled trial explores how cholecalciferol supplementation can affect cardiovascular and autonomic functions in obese or overweight patients, providing insights into its benefits beyond bone health and into cardiovascular regulation (Faria ACC et al., 2024).


Actions biochimiques/physiologiques

La vitamine D fonctionne à travers une récepteur qui fait partie de la famille des facteurs de transcription dépendant du ligand. Module la prolifération et la différentiation des cellules à la fois cancéreuses et normales. A des effets antiprolifératifs et anti-métastatiques sur les cellules cancéreuses de poumons, du colon et de la prostate. Les récepteurs activés de la vitamine D de l′intestin et des os maintiennent l′absorbance du calcium et l′homeostase.
Deficiency of vitamin D is often observed in chronic kidney disease.

Stockage et stabilité

Cholecalciferol C9756 is packaged under argon gas. If it is stored unopened at 2-8°C and protected from light, this product should be stable for a minimum of three years. Unused portions should be stored under nitrogen or argon gas. Deterioration is negligible after storage of one year in amber-evaculated ampules at refrigerator temperatures. It is oxidized and inactivated by moist air within a few days.

Produit(s) apparenté(s)

Pictogrammes

Skull and crossbonesHealth hazard

Mention d'avertissement

Danger

Mentions de danger

Classification des risques

Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral

Code de la classe de stockage

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Clinical Veterinary Toxicology, 448-448 (2003)
Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters
Matias P, et al.
Clinical journal of the American Society of Nephrology : CJASN, CJN-06510909 (2010)
Lin Fu et al.
Journal of immunology (Baltimore, Md. : 1950), 203(5), 1198-1207 (2019-07-19)
It is increasingly recognized that excessive glucocorticoids induce fetal intrauterine growth restriction (IUGR). Placental 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2), a glucocorticoid-catalyzing enzyme, prevents active glucocorticoids from maternal circulation into the fetus, thus protecting against IUGR. Previous studies demonstrated gestational LPS exposure
Stefan Pilz et al.
Hypertension (Dallas, Tex. : 1979), 65(6), 1195-1201 (2015-03-25)
Vitamin D deficiency is a risk factor for arterial hypertension, but randomized controlled trials showed mixed effects of vitamin D supplementation on blood pressure (BP). We aimed to evaluate whether vitamin D supplementation affects 24-hour systolic ambulatory BP monitoring values
Anders Burild et al.
Steroids, 98, 72-79 (2015-03-01)
Information regarding the endogenous storages of vitamin D3 after cutaneous vitamin D synthesis compared to oral vitamin D3 supplementation is sparse. Furthermore it is not known whether vitamin D3 can be stored for later use during periods of shortages of

Articles

Vitamin D and Prevention of Human Disease

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique